



(51) International Patent Classification:

C12N 15/09 (2006.01) C12N 15/66 (2006.01)
C12N 15/63 (2006.01) C12N 15/86 (2006.01)
C12N 15/64 (2006.01)

(21) International Application Number:

PCT/US2019/014122

(22) International Filing Date:

18 January 2019 (18.01.2019)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/619,392 19 January 2018 (19.01.2018) US

(71) Applicant: GENERATION BIO CO. [US/US]; 215 First Street, Suite 150, Cambridge, Massachusetts 02142 (US).

(72) Inventors: **ALKAN, Ozan**; c/o Generation Bio Co., 215 First Street, Suite 150, Cambridge, Massachusetts 02142 (US). **KOTIN, Robert Michael**; c/o Generation Bio Co., 215 First Street, Suite 150, Cambridge, Massachusetts 02142 (US). **STANTON, Matthew**; c/o Generation Bio Co., 215 First Street, Suite 150, Cambridge, Massachusetts 02142 (US). **KERR, Douglas Anthony**; c/o Generation Bio Co., 215 First Street, Suite 150, Cambridge, Massachusetts 02142 (US). **PELLETIER, Carolyn**; c/o Generation Bio Co., 215 First Street, Suite 150, Cambridge, Massachusetts 02142 (US).


(74) Agent: **BENN, Susanna C.** et al.; Nixon Peabody LLP, Exchange Place, 53 State Street, Boston, Massachusetts 02109 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: CLOSED-ENDED DNA VECTORS OBTAINABLE FROM CELL-FREE SYNTHESIS AND PROCESS FOR OBTAINING CEDNA VECTORS

FIG. 11B



(57) Abstract: The application describes methods for synthetic synthesis and cell-free synthesis of DNA vectors, particularly closed-ended DNA vectors (e.g., ceDNA vectors) having linear and continuous structure for delivery and expression of a transgene. The present invention relates to an in vitro process for production of closed-ended DNA vectors, corresponding DNA vector products produced by the methods and uses thereof, and oligonucleotides and kits useful in the process of the invention. DNA vectors produced using the methods described herein are free from unwanted side effects due to contaminants introduced during production in cell lines, for example, bacterial or insect cell lines. Further provided herein are methods and cell lines for reliable gene expression in vitro, ex vivo and in vivo using the ceDNA vectors synthesized using the methods herein.

[Continued on next page]

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

- *with international search report (Art. 21(3))*
- *with sequence listing part of description (Rule 5.2(a))*